Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial
Lancet Respir Med. 2023 Nov 15:S2213-2600(23)00389-2. doi: 10.1016/S2213-2600(23)00389-2. Online ahead of print.ABSTRACTBACKGROUND: Around 500 000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are needed. Following an interim analysis, we report the final safety and efficacy outcomes of the TB-PRACTECAL trial, evaluating the safety and efficacy of oral regimens for the treatment of rifampicin-resistant tuberculosis.METHODS: This open-label, randomised, controlled, multi-arm, multicentre, non-inferiority trial was conducte...
Source: Respiratory Care - November 19, 2023 Category: Respiratory Medicine Authors: Bern-Thomas Nyang'wa Catherine Berry Emil Kazounis Ilaria Motta Nargiza Parpieva Zinaida Tigay Ronelle Moodliar Matthew Dodd Varvara Solodovnikova Irina Liverko Shakira Rajaram Mohammed Rassool Timothy McHugh Melvin Spigelman David A Moore Koert Ritmeijer Source Type: research
Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis
Antimicrob Agents Chemother. 2023 Nov 15:e0078923. doi: 10.1128/aac.00789-23. Online ahead of print.ABSTRACTContezolid is a new oxazolidinone with in vitro and in vivo activity against Mycobacterium tuberculosis comparable to that of linezolid. Pre-clinical and clinical safety studies suggest it may be less toxic than linezolid, making contezolid a potential candidate to replace linezolid in the treatment of drug-resistant tuberculosis. We evaluated the dose-ranging activity of contezolid, alone and in combination with bedaquiline and pretomanid, and compared it with linezolid at similar doses, in an established BALB/c mou...
Source: Antimicrobial Agents and Chemotherapy - November 15, 2023 Category: Microbiology Authors: Deepak Almeida Si-Yang Li Jin Lee Barry Hafkin Khisimuzi Mdluli Nader Fotouhi Eric L Nuermberger Source Type: research
Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis
Antimicrob Agents Chemother. 2023 Nov 15:e0078923. doi: 10.1128/aac.00789-23. Online ahead of print.ABSTRACTContezolid is a new oxazolidinone with in vitro and in vivo activity against Mycobacterium tuberculosis comparable to that of linezolid. Pre-clinical and clinical safety studies suggest it may be less toxic than linezolid, making contezolid a potential candidate to replace linezolid in the treatment of drug-resistant tuberculosis. We evaluated the dose-ranging activity of contezolid, alone and in combination with bedaquiline and pretomanid, and compared it with linezolid at similar doses, in an established BALB/c mou...
Source: Antimicrobial Agents and Chemotherapy - November 15, 2023 Category: Microbiology Authors: Deepak Almeida Si-Yang Li Jin Lee Barry Hafkin Khisimuzi Mdluli Nader Fotouhi Eric L Nuermberger Source Type: research
Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis
Antimicrob Agents Chemother. 2023 Nov 15:e0078923. doi: 10.1128/aac.00789-23. Online ahead of print.ABSTRACTContezolid is a new oxazolidinone with in vitro and in vivo activity against Mycobacterium tuberculosis comparable to that of linezolid. Pre-clinical and clinical safety studies suggest it may be less toxic than linezolid, making contezolid a potential candidate to replace linezolid in the treatment of drug-resistant tuberculosis. We evaluated the dose-ranging activity of contezolid, alone and in combination with bedaquiline and pretomanid, and compared it with linezolid at similar doses, in an established BALB/c mou...
Source: Antimicrobial Agents and Chemotherapy - November 15, 2023 Category: Microbiology Authors: Deepak Almeida Si-Yang Li Jin Lee Barry Hafkin Khisimuzi Mdluli Nader Fotouhi Eric L Nuermberger Source Type: research
Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis: A systematic review and meta-analysis
Eur Respir J. 2023 Nov 9:2300639. doi: 10.1183/13993003.00639-2023. Online ahead of print.NO ABSTRACTPMID:37945030 | DOI:10.1183/13993003.00639-2023 (Source: Respiratory Care)
Source: Respiratory Care - November 9, 2023 Category: Respiratory Medicine Authors: Rubeshan Perumal Neda Bionghi Camus Nimmo Marothi Letsoalo Matthew J Cummings Madeleine Hopson Allison Wolf Shamim Al Jubaer Nesri Padayatchi Kogieleum Naidoo Michelle H Larsen Max O'Donnell Source Type: research
Treatment of MDR, pre-XDR, XDR and rifampicin resistant tuberculosis or in case of intolerance to at least rifampicin in Austria, Germany and Switzerland - Amendment dated 19.09.2023 to the Sk2-Guideline: Tuberculosis in adulthood of the German Central Committee against Tuberculosis (DZK) on behalf of the German Respiratory Society (DGP)
Pneumologie. 2023 Nov 6. doi: 10.1055/a-2182-1609. Online ahead of print.ABSTRACTIn December 2022, based on the assessment of new evidence, the World Health Organization (WHO) updated its guidelines for the treatment of drug-resistant tuberculosis (TB). The evaluation of both, these recommendations, and the latest study data, makes it necessary to update the existing guidelines on the treatment of at least rifampicin-resistant tuberculosis for the German-speaking region, hereby replacing the respective chapters. A shortened MDR-TB treatment of at least 6 month using the fixed and non-modifiable drug combination of bedaquil...
Source: Pneumologie - November 6, 2023 Category: Respiratory Medicine Authors: Ralf Otto-Knapp Torsten Bauer Folke Brinkmann Cornelia Feiterna-Sperling Inna Friesen Hilte Geerdes-Fenge Pia Hartmann Brit H äcker Barbara Hauer Walter Haas Jan Heyckendorf Martin Kuhns Christoph Lange Florian P Maurer Albert Nienhaus Martin Priwitzer E Source Type: research
Bedaquiline Resistance and Molecular Characterization of Rifampicin-Resistant Mycobacterium Tuberculosis Isolates in Zhejiang, China
(Source: Infection and Drug Resistance)
Source: Infection and Drug Resistance - October 30, 2023 Category: Infectious Diseases Tags: Infection and Drug Resistance Source Type: research
Programmatic management of bedaquiline-pretomanid-linezolid regimens in Georgia.
Conclusion: BPaL regimens showed excellent efficacy and good safety in program settings in Georgia. Urgent need to develop rapid tests for new drugs to avoid delaying adequate treatment. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Kiria, N., Avaliani, Z., Togonidze, T., Mikiashvili, L. Tags: Tuberculosis and non-tuberculous mycobacterial diseases Source Type: research
Frequency of serious adverse events on therapy with modified fully oral shorter treatment regimens (mSTR) for MDR/RR-TB
Conclusion: SAE occur during mSTR, but rarely lead to treatment discontinuation. Proper SAE monitoring and management are essential for any TB response. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Gurbanova, E., Yatskevich, N., Yedilbayev, A., Korotych, O., Hovhannesyan, A., Tyshko, M., Dankova, N., Skrahina, A. Tags: Tuberculosis and non-tuberculous mycobacterial diseases Source Type: research
Bedaquiline is effective in the treatment of Mycobacterium abscessus complex infection
Conclusions: The results of this study suggested that Bedaquiline is effective in the treatment of MABC infection regardless of colony morphotypes. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Huang, W.-C., Huang, Y.-W., Yang, C.-Y., Chen, H.-C. Tags: Translational science Source Type: research
